|Articles|October 18, 2021
Curia
Author(s)Curia
End-to-end contract research, development and manufacturing services for large and small molecules.
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s more than 3,700 employees at 29 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure.
Learn more at
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
5